Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.

Permalink
https://escholarship.org/uc/item/6r6956dp

Journal
Leukemia, 31(6)

ISSN
0887-6924

Authors
Yu, J
Chen, L
Cui, B
et al.

Publication Date
2017-06-01

DOI
10.1038/leu.2016.368

Peer reviewed
Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib

J Yu, L Chen, B Cui, Christina Wu, MY Choi, Y Chen, L Zhang, LZ Rassenti, GF Widhopf II and TJ Kipps

INTRODUCTION

CLL cells depend on interactions with cells and soluble factors present in the tumor microenvironment for proliferation and survival.1–3 Among the pathways that may support CLL proliferation and survival in vivo, BCR-signaling plays a prominent role.4 Crosslinking of the BCR leads to phosphorylation of CD79α/β and Src family kinase LYN, resulting in the recruitment and activation of the tyrosine kinase Syk, which induces a cascade of downstream signaling events, leading to enhanced B-cell survival.5 The importance of this cascade in CLL biology appears underscored by the clinical activity of small-molecule inhibitors of intracellular kinases, which play critical roles in BCR-signaling, such as SYK, phosphoinositide 3-kinase (PI3K) or Bruton's tyrosine kinase (BTK).5–7 Ibrutinib is a small molecule inhibitor of BTK that has proven highly effective in the treatment of patients with CLL. However, despite having excellent clinical activity, ibrutinib generally cannot eradicate the disease or induce durable responses in the absence of continuous therapy.7,8

The failure of ibrutinib to induce complete responses could be because of alternative survival-signaling pathways, which are not blocked by inhibitors of BTK. One such pathway is that induced by signaling through ROR1, an oncoembryonic antigen expressed on CLL cells, but not on normal postpartum tissues.9,10 We found that ROR1 could serve as a receptor for Wnt5a,9 which could induce non-canonical Wnt-signaling that activates Rho GTPases, such as Rac1, and enhance leukemia-cell proliferation and survival.11–13 Activation of Rac1 by Wnt5a could be inhibited by an anti-ROR1 mAb, cirmtuzumab, which is a first-in-class humanized monoclonal antibody currently undergoing evaluation in clinical trials for patients with CLL.14

We hypothesized that the effects of ibrutinib on blocking BCR-signaling might be offset by non-canonical Wnt-signaling via ROR1. If so, then inhibition of both ROR1- and BCR-signaling might have an enhanced anti-tumor effect. In this study, we investigated whether Wnt5a/ROR1 signaling was affected by treatment with ibrutinib and examined the activity of ibrutinib and cirmtuzumab on CLL cells in vitro and in vivo.

MATERIALS AND METHODS

Blood samples and animals

Blood samples were collected from CLL patients at the University of California San Diego Moores Cancer Center who satisfied diagnostic and immunophenotypic criteria for common B-cell CLL, and who provided written, informed consent, in compliance with the Declaration of Helsinki and the Institutional Review Board of the University of California San Diego (Institutional Review Board approval number 080918). PBMCs were isolated as described previously.15 All experiments with all mice were carried out in accordance with the guidelines of the National Institutes of Health for the care and use of laboratory animals, and University of California San Diego approved study protocol. All mice were age and sex matched. Details of assays for BTK-occupancy, calcium flux, Rac1 activation, cell proliferation, cell cycle and animal work are described in the Supplementary Materials and Methods Section.

RESULTS

Ibrutinib fails to inhibit Wnt5a-induced Rac1 activation in CLL

We examined the blood mononuclear cells of patients who were taking ibrutinib at the standard dose of 420 mg per day. Freshly isolated CLL cells had activated Rac1, which diminished over time in culture in serum-free media unless provided with exogenous

Received 19 July 2016; revised 24 October 2016; accepted 4 November 2016; accepted article preview online 1 December 2016; advance online publication, 3 January 2017
inhibited the calcium Figure S1C),18 without acutely affecting CLL-cell viability (Supplementary Figure S1B). On the other hand, we noted that ibrutinib at concentrations as low as 0.25 μm for subsequent studies. We examined for Wnt5a (Figures 1a and b), as noted for the CLL cells of patients not taking ibrutinib.13 Moreover, the CLL cells from ibrutinib-treated patients were incubated with or without Wnt5a and/or cirmtuzumab. Immunoblot analysis showed that Wnt5a-induced Rac1 activation in CLL cells from all patients examined, whereas treatment with cirmtuzumab inhibited Wnt5a-induced Rac1 activation (Figures 1c and d). These results indicate that therapy with ibrutinib does not inhibit ROR1-dependent, Wnt5a-induced Rac1 activation.

We determined whether treatment of CLL cells with ibrutinib in vitro could inhibit Wnt5a-induced Rac1 activation in CLL. For this, we incubated CLL cells collected from untreated patients with ibrutinib at concentrations of 0, 0.25, 0.5 or 1.0 μm for 2 h and then treated the cells with exogenous Wnt5a for 30 min. Immunoblot analysis demonstrated that ibrutinib did not block Wnt5a-induced Rac1 activation, even at ibrutinib concentrations of 1 μm (Supplementary Figure S1A), which is in excess of what is required to achieve 100% occupancy of BTK and inhibition of BTK activity (Supplementary Figure S1B).15 On the other hand, we noted that ibrutinib at concentrations as low as 0.25 μm inhibited the calcium flux induced by anti-IgM (Supplementary Figure S1C),16 without acutely affecting CLL-cell viability (Supplementary Figure S1D). The peak plasma concentration of ibrutinib in patients treated with this drug is ~0.5 μm, a concentration that can inhibit 100% occupancy and inhibition of BTK.19,20 Therefore, ibrutinib was used at 0.5 μm for subsequent studies. We examined for Wnt5a-induced Rac1 activation with or without ibrutinib and/or cirmtuzumab. CLL cells were cultured with ibrutinib, cirmtuzumab or both ibrutinib and cirmtuzumab for 2 h, and then stimulated with exogenous Wnt5a for 30 min. For comparison, cells from the same CLL sample were cultured without Wnt5a in parallel. Treatment of CLL cells with Wnt5a induced activation of Rac1 to levels that were significantly higher than that of CLL cells that were not treated with Wnt5a (Figures 1e and f). Treatment with cirmtuzumab, but not ibrutinib, could inhibit Wnt5a-induced Rac1 activation in CLL cells (Figures 1e and f). As expected, ibrutinib did not block the capacity of cirmtuzumab to inhibit Wnt5a-induced Rac1 activation (Figures 1e and f).13

Cirmtuzumab inhibits Wnt5a-enhanced proliferation of CLL cells treated with ibrutinib

Activation of Rac1-GTPase can enhance proliferation,11,13,21 whereas loss of Rac1 results in impaired hematopoietic-cell growth.22 We induced proliferation of CLL cells by co-culturing leukemia cells with HeLa cells expressing CD154 (HeLaCD154) and recombinant interleukin (IL)-4 and IL-10.12,23 Addition of exogenous Wnt5a to co-cultures of CLL cells with HeLaCD154 cells and IL-4/10 significantly enhanced the proportion of dividing CLL cells. Treatment of the CLL cells with cirmtuzumab, but not ibrutinib, could block Wnt5a-enhanced proliferation in CLL cells (Figure 2a). The same effects were observed for CLL cells of different patients (n = 6) (Figure 2b). As expected, co-culturing with HeLa cells in the presence of IL4/10 and/or Wnt5a could not induce CLL-cell proliferation (Supplementary Figure S2).

We also performed cell-cycle analysis on permeabilized leukemia cells using propidium iodide and found that Wnt5a stimulation significantly enhanced the fraction of CD154-stimulated leukemia cells in S/G2/M (Figures 2c and d). The capacity of Wnt5a to enhance the proportion of cells in S/G2/M could be inhibited by treatment with cirmtuzumab, but not ibrutinib (Figures 2c and d). Collectively, these data demonstrate that cirmtuzumab could block Wnt5a-signaling leading to enhanced leukemia-cell proliferation, which was not affected by treatment with ibrutinib.

Activity of cirmtuzumab and/or ibrutinib in CLL patient-derived xenografts

We transferred CLL cells into the peritoneal cavity of immunodeficient Rag2−/− γc−/− mice,24 and examined whether treatment with ibrutinib and/or cirmtuzumab could deplete CLL cells in vivo. For this, we injected 1 × 107 viable primary CLL cells in AIM-V medium into the peritoneal cavity of each mouse. One day later, the mice were provided no treatment or daily doses of ibrutinib...
at 15 mg/kg via oral gavage, and/or a single dose of cirmtuzumab at 1 mg/kg via i.p. injection. After 7 days, the CLL cells were harvested via peritoneal lavage and the proportions of CLL cells in the harvested peritoneal cells were examined by flow cytometry (Figure 3a). The percentages and total numbers of CLL cells in peritoneal lavage were significantly lower in mice treated with cirmtuzumab or ibrutinib than in mice that did not receive any treatment. However, significantly fewer CLL cells were found in the peritoneal lavage of mice treated with cirmtuzumab and ibrutinib than in the peritoneal lavage of mice treated with either agent alone (Figure 3b).

Cirmtuzumab, but not ibrutinib, inhibits Wnt5a-enhanced Rac1 activation and proliferation of ROR1 × TCL1 leukemia cells

ROR1 × TCL1 leukemia cells were isolated from ROR1 × TCL1 double-transgenic mice that developed ROR1+ leukemia.10 We pretreated ROR1 × TCL1 leukemia cells with ibrutinib or cirmtuzumab for 2 h and then cultured the cells with or without Wnt5a for 30 min. Similar to our findings with human CLL cells, Wnt5a-induced Rac1 activation could be inhibited by cirmtuzumab, but not by ibrutinib (Figures 4a and b). The combination of cirmtuzumab with ibrutinib also inhibited Wnt5a-induced activation of Rac1 to levels observed in untreated cells (Figures 4a and b). However, Wnt5a treatment could not induce activation of Rac1 in the leukemia cells of single-transgenic TCL1 mice, which develop a leukemia that lacks expression of ROR1 (Supplementary Figure S3A).10

Again, we induced proliferation of ROR1 × TCL1 leukemia cells by co-culturing the cells with HeLaCD154 in the presence of recombinant IL-4/10. Exogenous Wnt5a treatment significantly enhanced the percentage of numbers of cell divisions (Figure 4c). As with human CLL cells, Wnt5a and/or IL-4/10 alone could not induce proliferation of ROR1+ leukemia cells of ROR1 × TCL1 transgenic mice (Figure 4c), indicating a dependency on CD154 for this effect. In agreement with earlier studies,13 Wnt5a did not enhance the proliferation of ROR1-negative TCL1-leukemia cells co-cultured with HeLaCD154 cells and IL-4/10 (Supplementary Figure S3B), indicating a dependency on ROR1 for this effect. Treatment with ibrutinib could not inhibit the capacity of Wnt5a to enhance the proliferation of CD154-induced ROR1 × TCL1 leukemia cells proliferation. On the other hand, cirmtuzumab blocked the capacity of Wnt5a to enhance ROR1 × TCL1 leukemia cells proliferation in response to CD154 and IL-4/10 (Figure 4c).

As noted for human CLL cells, cell-cycle analysis on permeabilized ROR1 × TCL1 leukemia cells using propidium iodide demonstrated that Wnt5a could increase the fraction of CD154-stimulated ROR1+ leukemia cells in S/G2/M (Supplementary Figure S4). Moreover, the capacity of Wnt5a to enhance the fraction of ROR1+ leukemia cells in S/G2/M could be inhibited by treatment with cirmtuzumab, but not ibrutinib (Supplementary Figure S4).
Treatment of immunodeficient mice engrafted with ROR1 × TCL1 leukemia cells with cirmtuzumab and/or ibrutinib

We examined the capacity of cirmtuzumab and/or ibrutinib to inhibit ROR1 × TCL1 leukemia cell engraftment in Rag2−/− mice, which were each engrafted with 2 × 10⁴ ROR1 × TCL1 leukemia cells. These mice each received daily ibrutinib at 15, 5, 1.67 mg/kg via gavage, or a single dose of cirmtuzumab at 1, 3 or 10 mg/kg via intravenous injection. After 25 days, the animals were sacrificed and the spleen of each animal was examined. Ibrutinib (Supplementary Figure S5A) or cirmtuzumab (Supplementary Figure S5B) reduced the numbers of splenic leukemia cells in a dose-dependent manner. We selected the cirmtuzumab dose of 1 mg/kg and the daily dose of ibrutinib 5 mg/kg for combination studies. While the engrafted mice treated with cirmtuzumab or ibrutinib alone had significantly smaller spleens than the engrafted animals that did not receive any treatment, the mice treated with the combination of cirmtuzumab and ibrutinib had the greatest reductions in spleen size (Figure 5a). Furthermore, the mean proportion and number of leukemia cells in the spleen were significantly lower in mice treated with cirmtuzumab or ibrutinib compared with engrafted mice that did not receive treatment (Figures 5b and c). However, the engrafted animals that were treated with cirmtuzumab and ibrutinib had significantly lower proportions and numbers of leukemia cells per spleen than all other groups (Figures 5b and c).

Treatment of immunocompetent mice engrafted with ROR1 × TCL1 leukemia cells with cirmtuzumab and/or ibrutinib

We examined the capacity of cirmtuzumab and/or ibrutinib to inhibit engraftment of ROR1 × TCL1 leukemia cells (CD5− B220lowROR1−) in immunocompetent human-ROR1 transgenic (ROR1-Tg) mice. We injected 2 × 10⁴ ROR1 × TCL1 leukemia cells to ROR1-Tg mice, and administered no treatment, daily doses of ibrutinib at 5 mg/kg via gavage, or weekly doses of cirmtuzumab at 10 mg/kg via intravenous injection. After 28 days, the animals were sacrificed and the spleen of each animal was examined. While the engrafted mice treated with cirmtuzumab or ibrutinib alone had significantly smaller spleens than the engrafted animals that did not receive any treatment, the mice treated with the combination of cirmtuzumab and ibrutinib had the greatest reductions in spleen size (Figure 6a). Furthermore, the mean proportion of splenocytes that were leukemia cells and the average absolute number of leukemia cells in the spleen were significantly lower in mice treated with either cirmtuzumab or ibrutinib than in mice that did not receive any treatment (Figures 6b and c). However, the engrafted animals that were treated with cirmtuzumab and ibrutinib had significantly lower proportions and numbers of leukemia cells per spleen than all other groups (Figures 6b and c).
In this study, we examined the CLL cells of patients undergoing treatment with ibrutinib, which is highly effective at inhibiting BCR-signaling through its capacity to inhibit BTK.25,26 First, we noted that the CLL cells of patients treated with ibrutinib had activated Rac1, which diminished over time in culture in serum-free media unless we supplemented the media with exogenous Wnt5a. Moreover, we found that Wnt5a could induce CLL to activate Rac1, as noted in a variety of cell types,27–29 including CLL cells.13 Subsequent studies showed that Wnt5a could induce Rac1 activation even in CLL cells that were treated with ibrutinib at supra-physiologic concentrations, which exceeded the levels required to achieve 100% occupancy and inhibition of BTK and BCR-signaling. In some respects this is similar to the findings of Ren and colleagues, who reported that ibrutinib could not inhibit FcyR-induced Rac1 activation, even though it could inhibit FcyR-induced calcium signaling and cytokine production.17 However, the Wnt5a-signaling noted in our study was dependent upon ROR1, as indicated by the capacity of cirmtuzumab to inhibit Wnt5a-induced activation of Rac1. We conclude that ibrutinib cannot block ROR1-dependent, Wnt5a-induced activation of Rac1, which serves as an intracellular signal transducer that can influence multiple signaling pathways.

Activated Rac1 might mitigate the effectiveness of anti-cancer therapy. Prior studies found that activated Rac1 can enhance the resistance of CLL cells to cytotoxic drugs.11 One study found that activated T cells and fibroblasts could induce CLL cells to activate Rac1 and acquire resistance to the cytotoxic effects of fludarabine monophosphate; inhibition of activated Rac1 could restore the sensitivity of these CLL cells to this drug.11 In another study, Rac1 was found to interact with and enhance the function of Bcl-2,30 which is over-expressed in CLL.31 Another study involving acute leukemia cells found that treatment with NSC-23766, an inhibitor of activated Rac1, could enhance the cytotoxicity of Bcl-2 antagonists for leukemia cells.32 Finally loss of p53 in lymphoma cells has been associated with increased activation of Rac1, which could be inhibited by NSC-23766 or a dominant-negative form of Rac1, Rac1N17, leading to a dose-dependent increase in the rate of spontaneous or drug-induced apoptosis.33 Conceivably the activated Rac1 observed in CLL cells of patients treated with ibrutinib provides an ancillary signal, which enhances the survival of leukemia cells of patients treated with ibrutinib.

Furthermore, Wnt5a-signaling also could promote leukemia-cell proliferation in patients treated with ibrutinib. The functional consequences of Wnt5-signaling in part are demonstrated by the ability of Wnt5a to enhance proliferation induced by CD154, which can induce CLL proliferation in vitro in the presence of exogenous IL4/10 or IL-21.13,23,34 Although ibrutinib partially could inhibit the capacity to inhibit BCR and BCR-independent pathways,25,26,35 we found that ibrutinib could not inhibit the capacity of Wnt5a to enhance CD154-induced CLL proliferation via ROR1-dependent signaling, which could, however, be blocked by treatment with cirmtuzumab. Wnt5a most likely is produced by cells in the CLL microenvironment. However, prior studies found that plasma samples of patients with CLL also have high levels of Wnt5a relative to those of healthy adults.13 Wnt5a also might be produced by the CLL cells.
themselves, allowing for autocrine activation. Indeed, one study found that CLL cells that express high levels of Wnt5a apparently have increased motility and chemotactic responses than CLL cells that express little or no Wnt5a, presumably due to the effects of Wnt5a-autocrine signaling. We also noted in an earlier study that Wnt5a could enhance the migration of CLL cells toward chemokine via activation of RhoA. However, because BTK plays a prominent role in CLL signaling via chemokine receptors such as CXCR4, we focused our attention on the capacity of Wnt5a to activate Rac1, which could enhance proliferation induced by CD154 via signaling pathways that are relatively independent of BTK.

Because the Wnt5a-ROR1 signaling pathway appears intact in CLL cells treated with ibrutinib, we examined for additive, if not synergistic, effects of treatment with ibrutinib and cirmtuzumab. For mice engrafted with histocompatible ROR1+ leukemia, or human CLL xenografts, we found that treatment with both cirmtuzumab and ibrutinib was significantly more effective than treatment with either agent alone in clearing leukemia cells in vivo. This study indicates that cirmtuzumab may enhance the activity of ibrutinib in the treatment of patients with CLL or other ROR1+ B-cell malignancies.

Combination therapies are often more effective in treating patients with cancer. Investigations are ongoing to evaluate the activity of ibrutinib in combination with other drugs, such as venetoclax or anti-CD20 mAbs. However, other agents that target signaling pathways that are relatively independent of those influenced by BCR-signaling also could make excellent candidates for use in combination with ibrutinib. Because cirmtuzumab and ibrutinib target independent signaling pathways, they have apparent synergistic effects in clearing leukemia cells from our mouse models. By targeting more than one signaling pathway leading to leukemia-cell growth/survival, combined therapy with cirmtuzumab and ibrutinib also could potentially mitigate the risk of acquiring resistance to inhibitors of BTK, as sometimes occurs in patients who receive ibrutinib monotherapy.

Taken together, from the perspective of therapeutic efficacy and drug resistance, our preclinical observations provide a rationale for the combination therapy with cirmtuzumab with ibrutinib, or other inhibitors of BTK such as acalabrutinib, for patients with CLL or other B-cell malignancies that express ROR1.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank Dr Brian Lannutti for technical support. We thank California Institute for Regenerative Medicine (CIRM) grant (DR3-06924) for supporting us in the generation of the anti-ROR1 mAb, cirmtuzumab. This work was supported by the UC San Diego Foundation Blood Cancer Research Fund (BCRF), a SPORE grant (7005-14) from the Leukemia and Lymphoma Society, and a P01 grant (5P01CA081534-14) from the NIH for the CLL Research Consortium.

AUTHOR CONTRIBUTIONS

JY, LC and TJK conceived the project. JY, LC and TJK wrote the manuscript. JY, LC, BC, CW, MYC, YC, LZ, LZR and GFW performed the experiments. JY, LC and TJK analyzed the data.
25. Herman SE, Mustafa RZ, Gaymfi JA, Pittaluga S, Chang S, Chang B et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. *Blood* 2014; 123: 3286–3295.

26. Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. *Leukemia* 2014; 28: 649–657.

27. Nishita M, Itsukushima S, Nomachi A, Endo M, Wang Z, Inaba D et al. Ror2/FRizzled complex mediates Wnt5a-induced AP-1 activation by regulating Dishevelled polymerization. *Mol Cell Biol* 2010; 30: 3610–3619.

28. Naskar D, Maiti G, Chakraborty A, Roy A, Chattopadhyay D, Sen M. Wnt5a-Rac1- NF-kappaB homeostatic circuit sustains innate immune functions in macrophages. *J Immunol* 2014; 192: 4386–4397.

29. Zhu Y, Shen T, Liu J, Zheng J, Zhang Y, Xu R et al. Rab35 is required for Wnt5a-Dvl2-induced Rac1 activation and cell migration in MCF-7 breast cancer cells. *Cell Signal* 2013; 25: 1075–1085.

30. Velatihan R, Kang J, Haripra JL, Loh T, Goh BC, Le Bras M et al. The small GTPase Rac1 is a novel binding partner of Bcl-2 and stabilizes its antiapoptotic activity. *Blood* 2011; 117: 6214–6226.

31. Roberts AW, Seymour JF, Styr JN, Wieda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase 1 study of navitoclax in patients with relapsed or refractory disease. *J Clin Oncol* 2012; 30: 488–496.

32. Mizukawa B, Wei J, Shrestha M, Wunderlich MR, Atlas R, Gobin YP et al. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. *Blood* 2011; 118: 5235–5243.

33. Bosco EE, Ni W, Wang L, Guo F, Johnson JF, Zheng Y. Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis. *Blood* 2010; 115: 3320–3328.

34. Pasquato MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. *Blood* 2013; 122: 3010–3019.

35. Guo A, Lu P, Galanina N, Nabhani C, Smith SM, Coleman M et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. *Oncoarget* 2017; 6: 4598–4610.

36. Janosvics P, Poppova L, Plevova K, Plesingehora H, Behal M, Kaucha M et al. Autocrine signaling by Wnt5a deregulates chemotaxis of leukemic cells and predicts clinical outcome in chronic lymphocytic leukemia. *Clin Cancer Res* 2016; 22: 459–469.

37. O’Hare M, Salangla CL, Kipps TJ, Messmer D, Dorestein PC, Handel TM. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. *PLOS One* 2010; 5: e11176.

38. Woodcock J, Griffin JP, Behrmann RE. Development of novel combination therapies. *N Engl J Med* 2011; 364: 985–987.

39. Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A et al. Ibrutinib in combination with rituximab and irinotecan for IgM-MALT lymphoma: implications for combination therapy. *Haematologica* 2015; 100: 77–86.

40. Skarzynski M, Niemann CU, Lee YS, Martyr S, Maric I, Salem D et al. Interactions between ibrutinib and Anti-CD20 antibodies: competing effects on the outcome of combination therapy. *Clin Cancer Res* 2016; 22: 86–95.

41. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS et al. Sampling of circulating tumor cells in chronic lymphocytic leukemia using cellfree DNA. *Cancer Genet* 2016; 246: 256–262.

42. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. *J Hematol Oncol* 2016; 9: 21.

43. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N Engl J Med* 2016; 374: 323–332.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/